Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments

Molecular Cancer Therapeutics

Volumn 14, Issue 4, 2015, Pages 952-963

  Loganzo, Frank ^a   Tan, Xingzhi ^a   Sung, Matthew ^a   Jin, Guixian ^a   Myers, Jeremy S ^a   Melamud, Eugene ^a   Wang, Fang ^a   Diesl, Veronica ^a   Follettie, Maximillian T ^a   Musto, Sylvia ^a   Lam, My Hanh ^a   Hu, William ^a   Charati, Manoj B ^a   Khandke, Kiran ^a   Kim, Kenny Sung Kyoo ^a   Cinque, Mike ^a   Lucas, Judy ^a   Graziani, Edmund ^a   Maderna, Andreas ^a   O'Donnell, Christopher J ^a   Arndt, Kim T ^a   Gerber, Hans Peter ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; TRASTUZUMAB; TRASTUZUMAB MAYTANSINOID ANTIBODY CONJUGATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MEMBRANE ANTIGEN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; PROTEOME; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER CELL LINE; CANCER RESISTANCE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; FEMALE; IMMUNOBLOTTING; LONG TERM EXPOSURE; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IC50; METABOLISM; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOCONJUGATES; INHIBITORY CONCENTRATION 50; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROTEIN TRANSPORT; PROTEOME; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TRASTUZUMAB; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941656661     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0862     Document Type: Article

References (48)

1. Lambert JM, Chari RV. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 2014;57:6949-64.
2. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102: 1458-65.
3. Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Invest Drugs 2011;20: 1131-49.
4. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature Rev Cancer 2013;13:714-26.
5. de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007;62:214-26.
6. Fletcher JI, Haber M,Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nature Rev Cancer 2010;10:147-56.
7. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5: 219-34.
8. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nature Rev Cancer 2010;10:194-204.
9. Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, et al. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. Mol Cancer Ther 2004;3:1319-27.
10. Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008;18:73-9.
11. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nature Rev Cancer 2009;9:28-39.
12. Nahta R, Esteva FJ. Herceptin:mechanisms of action and resistance. Cancer Lett 2006;232:123-38.
13. Dokmanovic M, Hirsch DS, Shen Y, Wu WJ. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol Cancer Ther 2009;8:1557-69.
14. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Rev Cancer 2008;8:592-603.
15. Starling JJ,Maciak RS, Hinson NA, Hoskins J, Laguzza BC, Gadski RA, et al. In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates. Cancer Res 1990;50:7634-40.
16. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 2014;16:R22.
17. Phillips GL. Mechanisms of acquired resistance to Trastuzumab emtansine (T-DM1). World ADC Summit; 2011 Oct 25-28; San Francisco, CA: London: Hanson Wade Limited.
18. Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, et al. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 2014;20:456-68.
19. Lewis TS, Gordon K, Li F, Weimann A, Bruders R, Miyamoto JB, et al. Characterization and circumvention of drug resistance mechanisms in SGN-35-resistant HL and ALCL clonal cell lines [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA: Philadelphia (PA): AACR.
20. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004;3:1585-92.
21. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-31.
22. Schwender H. siggenes: Multiple testing using SAM and Efron's empirical Bayes approaches. R package version 1.32.0 ed2012.
23. Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res 2013;41:W77-83.
24. Maderna A, Doroski M, Subramanyam C, Porte A, Leverett CA, Vetelino BC, et al. Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications. J Med Chem 2014;57:10527-43.
25. Tumey LN, Charati M, He T, Sousa E, Ma D, Han X, et al. Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. Bioconjug Chem 2014;25:1871-80.
26. Burkhart CA, Watt F, Murray J, Pajic M, Prokvolit A, Xue C, et al. Smallmolecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res 2009;69:6573-80.
27. Mirski SE, Gerlach JH, Cole SP.Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 1987;47:2594-8.
28. Grigoriev I, Splinter D, Keijzer N, Wulf PS, Demmers J, Ohtsuka T, et al. Rab6 regulates transport and targeting of exocytotic carriers. Developmental Cell 2007;13:305-14.
29. Callow MG, Zozulya S, Gishizky ML, Jallal B, Smeal T. PAK4 mediates morphological changes through the regulation of GEF-H1. J Cell Sci 2005;118:1861-72.
30. Scott DB, Michailidis I, Mu Y, Logothetis D, Ehlers MD. Endocytosis and degradative sorting of NMDA receptors by conserved membrane-proximal signals. J Neurosci 2004;24:7096-109.
31. Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473-82.
32. Koninki K, Barok M, Tanner M, Staff S, Pitkanen J, Hemmila P, et al. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 2010;294: 211-9.
33. Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011;13:R46.
34. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21: 46-53.
35. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-5.
36. Phillips GDL, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
37. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24.
38. Hanson PI,Cashikar A. Multivesicular body morphogenesis. Annu RevCell Dev Biol 2012;28:337-62.
39. Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol 2004;5:121-32.
40. Rotin D, Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 2009;10:398-409.
41. Li X, Zhou Q, Sunkara M, Kutys ML, Wu Z, Rychahou P, et al. Ubiquitylation of phosphatidylinositol 4-phosphate 5-kinase type I gamma by HECTD1 regulates focal adhesion dynamics and cell migration. J Cell Sci 2013;126:2617-28.
42. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, et al. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 2010;70:1204-14.
43. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7.
44. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13:4909-19.
45. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-inducedHER reprogramming in "resistant" breast carcinoma cells. Cancer Res 2009;69:2191-4.
46. Pohlmann PR,Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15:7479-91.
47. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010;21:255-62.
48. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6: 117-27.